LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Open

SectorGezondheidszorg

10.06 0.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.86

Max

10.18

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+174.51% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	159M 1B
Vorige openingsprijs	9.86
Vorige sluitingsprijs	10.06

Nieuwssentiment

By Acuity

100%

323 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 mei 2026, 22:47 UTC

Winsten

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mei 2026, 20:45 UTC

Winsten

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mei 2026, 23:39 UTC

Marktinformatie

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mei 2026, 23:31 UTC

Marktinformatie

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mei 2026, 23:17 UTC

Marktinformatie

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mei 2026, 23:02 UTC

Marktinformatie

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mei 2026, 22:37 UTC

Marktinformatie

Acquisities, Fusies, Overnames

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mei 2026, 21:12 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mei 2026, 21:00 UTC

Winsten

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mei 2026, 20:57 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:55 UTC

Winsten

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

28 mei 2026, 20:48 UTC

Populaire aandelen

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mei 2026, 20:34 UTC

Winsten

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mei 2026, 20:31 UTC

Winsten

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mei 2026, 20:28 UTC

Winsten

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mei 2026, 20:26 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Membership Fees $1.37B

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Net Sales $69.15B

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

174.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 174.51%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

323 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.